Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00092924
Status:
COMPLETED
Last Update Posted:
2013-08-02
First Post:
2004-09-24
Brief Title:
Study of TRM-1TRAIL-R1 Monoclonal Antibody in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer NSCLC
Sponsor:
Human Genome Sciences Inc
Organization:
Human Genome Sciences Inc
Study Overview
Official Title:
A Phase 2 Multi-Center Open-Label Study to Evaluate the Efficacy Safety and Tolerability of TRM-1 Fully Human Monoclonal Antibody To TRAIL-R1 in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None